General Assembly Raised Bill No. 866
January Session, 2017 LCO No. 4303
*04303_______GL_*
Referred to Committee on GENERAL LAW
Introduced by:
(GL)
General Assembly
Raised Bill No. 866
January Session, 2017
LCO No. 4303
*04303_______GL_*
Referred to Committee on GENERAL LAW
Introduced by:
(GL)
AN ACT CONCERNING CANNABIDIOL PRESCRIPTION MEDICATION.
Be it enacted by the Senate and House of Representatives in General Assembly convened:
Section 1. (NEW) (Effective July 1, 2017) If a cannabidiol investigational product is newly approved or rescheduled by the federal Food and Drug Administration, as a prescription medication, as defined in section 17b-499 of the general statutes, such investigational product shall be deemed approved as a prescription medication in this state.
This act shall take effect as follows and shall amend the following sections:
Section 1 July 1, 2017 New section
This act shall take effect as follows and shall amend the following sections:
Section 1
July 1, 2017
New section
Statement of Purpose:
To provide a potential treatment for children and adults with epilepsy.
[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is not underlined.]